Valerya Semenisty

Statistics

Publications

Citations

635

H-Index

Active since

2019

Affiliations

Hebrew University of Jerusalem(Current)

Hospital Universitario de Fuenlabrada

Cornell University

Rambam Health Care Campus

Clinica Universidad de Navarra

Valerya Semenisty is an author at Hebrew University of Jerusalem specializing in cancer immunotherapy, pancreatic cancer, and pancreatic cancer pharmacotherapy.

Publications per year

2019–2021

Publications

BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial

Bruno Bockorny, Valerya Semenisty, Teresa Macarulla et al. · Nature Medicine · 2020 · 533 citations

Medicine, Oncology, Pharmacology +11

Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial

Bruno Bockorny, Teresa Macarulla, Valerya Semenisty et al. · Clinical Cancer Research · 2021 · 88 citations · Full text

Medicine, Oncology, Pharmacology +17

A Multi-Center Phase IIA Trial to Assess the Safety and Efficacy of BL-8040 (a CXCR4 Inhibitor) in Combination with Pembrolizumab and Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma (PDAC)

Manuel Hidalgo, Valerya Semenisty, Bruno Bockorny et al. · Annals of Oncology · 2019 · 14 citations

Medicine, Oncology, Pharmacology +15

1–3 of 3